ArticleCombinatorial chemistry & high throughput screening2026
Macrophage HERC6 Promotes NAFLD: Integrated Analyses of Mendelian Randomization and Single-Cell Transcriptome.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
AIMS AND
objectivesThis study aimed to explore the relationship between HERC6- associated immune response and Non-Alcoholic Fatty Liver Disease (NAFLD) and to screen drug candidates for novel treatments. MATERIALS AND
methodsMendelian Randomization (MR) was performed to test the relationship between a genetically predicted increase in HERC6 expression and the development of NAFLD. A single-cell RNA-seq profile of liver tissue with histological characteristics (GSE168933) was obtained. The immune cell type with the highest HERC6 score was identified, and the HERC6 scores across hepatic steatosis, ballooning, and lobular inflammation were compared. Bulk RNA data of liver samples from obese patients who underwent diet restriction or bariatric surgery (GSE83452) was deconvoluted, and the proportions of distinct HERC6-high immune cell subpopulations were estimated. The baseline and follow-up differences were compared to evaluate the effectiveness of different therapies. Finally, a single-cell drug susceptibility assessment was performed to screen drug candidates targeting HERC6-associated immune cells.
resultsMR results showed that an increase in HERC6 expression was associated with an increase in low-density lipoprotein cholesterol (LDL-C) level and the development of NAFLD. The HERC6 score on monocyte-derived macrophage was the highest and positively correlated with hepatic steatosis, ballooning, and lobular inflammation. The HERC6-high macrophage fraction significantly decreased after bariatric surgery but not diet therapy. Triptolide was identified as a potential drug for NAFLD targeting HERC6-high macrophages.
conclusionThe results highlighted the role of hepatic macrophage HERC6 in NAFLD.
Indexed as
Identifiers
39754760What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.